New anti-cancer drug combo treatment shows promise for myeloma patients
Phase 3 trial results reveal that selinexor – a relatively new anti-cancer drug – improves patient outcomes when combined with established treatments.
Cancer-causing HTLV-1 virus hijacks cellular machinery to establish infection
Scientists have used a cutting-edge visualisation technique to show how the human T-cell lymphotropic virus, type 1 (HTLV-1) infects immune cells.
Agilent Measurement Suite celebrates early successes
Advanced chemical analysis equipment from Agilent in the Molecular Sciences Research Hub has been helping researchers solve pressing challenges.
Potential therapeutic targets for cancer-causing virus uncovered by new research
Scientists have discovered key factors that control the genome maintenance and replication of a virus responsible for a rare form of cancer.
New way to tackle disease-causing proteins wins €20k in innovation competition
A team of international students and postdocs, including an Imperial researcher, have won the Merck Innovation Cup for their new drug innovation.
Bacteria ‘factories’ used to discover potential new malaria drugs
Researchers have engineered bacteria to produce new versions of a potential antibiotic molecule, some with potent antimalarial properties.
Feature
Four ways Imperial is leading the fight against Parkinson’s
In the lead up to World Parkinson’s Day on 11 April, we reflect on how Imperial scientists are advancing research to tackle the condition.
New COVID-19 project will use the power of smartphones to search for treatments
Imperial researchers will look for potential new treatments for COVID-19 using the computing power of people’s smartphones.
25
Imperial physicist and chemist honoured in premier young scientist awards
Professor Claudia de Rham and Professor Matthew Fuchter receive accolades in the annual Blavatnik Awards for Young Scientists.
Cell ‘hands’ to unlock doors in health research, drug design, and bioengineering
A previously overlooked cell membrane protein could help to further cancer research, drug design, and bioengineering, according to new research.
